{"entity":{"id":"nct05558007","kind":"trial","name":"Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients","aka":[],"tldr":"A phase 2 trial of Tadalafil 5mg in prostate cancer, run by Biozeus Biopharmaceutical S.A., now recruiting.","summary":"Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients is a phase 2 interventional study registered as NCT05558007 by Biozeus Biopharmaceutical S.A., with 72 participants planned, started 2023-11-22 and due to reach its primary completion in 2024-12-31. Interventions recorded: Tadalafil 5mg, BZ371A, Oral Placebo and Topical Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05558007","url":"https://clinicaltrials.gov/study/NCT05558007"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05558007","phase":"2","setting":"Phase 2 Clinical Trial to Evaluate Safety and Efficacy of BZ371A in a Gel Applied in Patients That Performed Radical Prostatectomy","sponsor":"Biozeus Biopharmaceutical S.A.","enrolled":72,"outcomes":[]},"route":"/trials/nct05558007/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}